121 related articles for article (PubMed ID: 38316193)
1. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.
Perrier L; Balusson F; Morelle M; Castelli J; Thariat J; Benezery K; Hasbini A; Gery B; Berger A; Liem X; Guihard S; Chapet S; Thureau S; Auberdiac P; Pommier P; Ruffier A; Devillers A; Oger E; Campillo-Gimenez B; de Crevoisier R
Radiother Oncol; 2024 Apr; 193():110116. PubMed ID: 38316193
[TBL] [Abstract][Full Text] [Related]
2. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.
Castelli J; Thariat J; Benezery K; Hasbini A; Gery B; Berger A; Liem X; Guihard S; Chapet S; Thureau S; Auberdiac P; Pommier P; Ruffier A; Perrier L; Devillers A; Campillo-Gimenez B; de Crevoisier R
JAMA Oncol; 2023 Aug; 9(8):1056-1064. PubMed ID: 37261806
[TBL] [Abstract][Full Text] [Related]
3. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.
Castelli J; Simon A; Louvel G; Henry O; Chajon E; Nassef M; Haigron P; Cazoulat G; Ospina JD; Jegoux F; Benezery K; de Crevoisier R
Radiat Oncol; 2015 Jan; 10():6. PubMed ID: 25573091
[TBL] [Abstract][Full Text] [Related]
4. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Nutting CM; Morden JP; Harrington KJ; Urbano TG; Bhide SA; Clark C; Miles EA; Miah AB; Newbold K; Tanay M; Adab F; Jefferies SJ; Scrase C; Yap BK; A'Hern RP; Sydenham MA; Emson M; Hall E;
Lancet Oncol; 2011 Feb; 12(2):127-36. PubMed ID: 21236730
[TBL] [Abstract][Full Text] [Related]
5. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Cohort Study Analyzing Radiation-Induced Xerostomia and Quality of Life of Head and Neck Cancer Patients Treated With Intensity-Modulated Radiotherapy and 3D Conformal Radiotherapy Techniques at a Tertiary Cancer Center in Eastern India.
Sahoo B; Padhi S; Patra AC; Mahapatra BR; Mishra T; Mishra SR; Patro KC
Cureus; 2023 Mar; 15(3):e36442. PubMed ID: 37090370
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer.
Yong JH; Beca J; O'Sullivan B; Huang SH; McGowan T; Warde P; Hoch JS
Clin Oncol (R Coll Radiol); 2012 Sep; 24(7):532-8. PubMed ID: 22739256
[TBL] [Abstract][Full Text] [Related]
8. Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and-neck cancer.
Maheshwari G; Dhanawat A; Kumar HS; Sharma N; Jakhar SL
J Cancer Res Ther; 2020; 16(3):600-604. PubMed ID: 32719274
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
[TBL] [Abstract][Full Text] [Related]
10. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
[TBL] [Abstract][Full Text] [Related]
11. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
12. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis.
Marta GN; Weltman E; Ferrigno R
Rev Assoc Med Bras (1992); 2018 Apr; 64(4):318-323. PubMed ID: 30133610
[TBL] [Abstract][Full Text] [Related]
14. Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer.
Zhang P; Simon A; Rigaud B; Castelli J; Ospina Arango JD; Nassef M; Henry O; Zhu J; Haigron P; Li B; Shu H; De Crevoisier R
Radiother Oncol; 2016 Jul; 120(1):41-7. PubMed ID: 27372223
[TBL] [Abstract][Full Text] [Related]
15. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
16. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
17. Adaptive radiotherapy for head and neck cancer.
Castelli J; Simon A; Lafond C; Perichon N; Rigaud B; Chajon E; De Bari B; Ozsahin M; Bourhis J; de Crevoisier R
Acta Oncol; 2018 Oct; 57(10):1284-1292. PubMed ID: 30289291
[TBL] [Abstract][Full Text] [Related]
18. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck.
Jensen AD; Debus J
Radiat Oncol; 2019 Nov; 14(1):194. PubMed ID: 31694720
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
